Cimerli Disease Interactions

Drugs requiring intravitreal administration (including aflibercept, faricimab, pegaptanib, and ranibizumab) are contraindicated in patients with active intraocular inflammation or ocular/periocular infections; intravitreal injections have been associated with endophthalmitis. Patients should be advised to seek immediate medical attention from an ophthalmologist if the eye becomes red, photosensitive, or painful, or if a change in vision occurs in the days following drug administration.

Increases in intraocular pressure have been reported both pre- injection and post- injection (at 60 minutes) while being treated with ranibizumab. Intraocular pressure should be monitored prior and following intravitreal injection with ranibizumab and managed appropriately.